Outlook Therapeutics, Inc. (OTLK) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US69012T3059
Outlook Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.41 m USD |
| Gross profit | 57,205.00 USD |
| Operating income | -67.06 m USD |
| EBIT | -64.07 m USD |
| Net income | -62.42 m USD |
| Diluted EPS – continuing operations | -1.79 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
More stocks
- Hispanotels Inversiones SOCIMI SA (YHSP.MC)
- Meta Wolf (WOLF.DE)
- MAGNACHIP SEMICONDUCTOR Corp (MX)
- YFC-BonEagle Electric Co Ltd (6220.TWO)
- Shanghai Kai Kai Industry Co Ltd B (900943.SS)
- Raontec Inc (232680.KQ)
- Bancorp 34, Inc. (BCTF)
- BNCCorp Inc (BNCC)
- Jati Tinggi Group Berhad (0292.KL)
- Info-Tek (8183.TWO)
- Indonesia Fibreboard Industry PT (IFII.JK)
- Silla Co.Ltd (004970.KS)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.